Denlinger, Crystal S. http://orcid.org/0000-0002-5663-7751
Keedy, Vicki L.
Moyo, Victor
MacBeath, Gavin
Shapiro, Geoffrey I.
Article History
Received: 30 April 2021
Accepted: 22 June 2021
First Online: 11 July 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all patients in the study.
: All authors and the sponsor of the study gave consent to publication of this study.
: <b>CSD</b> has received institutional research funding from Advaxis, Agios Pharmaceuticals, Amgen, Array BioPharma, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Eli Lilly & Co, Exelixis, Genentech, Genmab, ImClone, InCyte, Lycera, Macrogenics, MedImmune, Merrimack Pharmaceuticals, Inc., OncoMed, Pfizer, Sanofi Aventis, and Zymeworks. She has served on advisory boards for Astellas, Bayer, BeiGene, Bristol Myers Squibb, Carevive, Eli Lilly & Co, EMD Serono, Exelixis, Merck, Merrimack Pharmaceuticals, Inc., and Taiho, and on a data safety monitoring board for Zymeworks. She has received writing support from Pfizer.<b>VLK</b> has received institutional research funding from Adaptimmune, Advenchen, AstraZeneca, Bayer, Bristol Myers Squibb, CytRx, Daiichi Sankyo, Deciphera, Eli Lilly & Co, Genentech, ImClone, Immune Design, MedPacto, Merrimack Pharmaceuticals, Inc., Pfizer, Plexxikon, Roche, Sanofi Aventis, Springworks, Tracon, and Threshold. She has served on advisory boards for Daiichi Sankyo, Janssen, and Karyopharm.<b>VM</b> was previously an employee of Merrimack Pharmaceuticals, Inc. during the period of study conduct and is a co-inventor on some patents relating to seribantumab and other Merrimack Products, but currently does not own any stock/stock options at Merrimack Pharmaceuticals, Inc. He is currently an employee and equity holder at L.E.A.F. Pharmaceuticals and LEAF4Life Inc.<b>GM</b> was a founder, employee, and shareholder of Merrimack Pharmaceuticals, Inc. and is an inventor on patents relating to seribantumab. He is currently the Chief Scientific Officer of TScan Therapeutics.<b>GIS</b> has received research funding from Eli Lilly & Co, Merck KGaA/EMD-Serono, Merck, and Sierra Oncology. He has served on advisory boards for Almac, Angiex, Artios, Asana, Astex, Atrin, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Concarlo Holdings, Cybrexa Therapeutics, CytomX Therapeutics, Daiichi Sankyo, Eli Lilly & Co, Fusion Pharmaceuticals, G1 Therapeutics, ImmunoMet, Ipsen, Merck KGaA/EMD-Serono, Pfizer, Roche, Seattle Genetics, Sierra Oncology, Syros, and Zentalis. In addition, he holds a patent entitled, “Dosage regimen for sapacitabine and seliciclib,” also issued to Cyclacel Pharmaceuticals, and a pending patent entitled, “Compositions and Methods for Predicting Response and Resistance to CDK4/6 Inhibition,” together with Liam Cornell.